Attached files
| file | filename |
|---|---|
| 10-Q - PROVECTUS BIOPHARMACEUTICALS, INC. | form10-q.htm |
| EX-31.2 - PROVECTUS BIOPHARMACEUTICALS, INC. | ex31-2.htm |
| EX-31.1 - PROVECTUS BIOPHARMACEUTICALS, INC. | ex31-1.htm |
Exhibit 32
CERTIFICATION PURSUANT TO RULE 13a-14(b) UNDER
THE SECURITIES EXCHANGE ACT OF 1934 AND
SECTION 1350 OF CHAPTER 63 OF TITLE 18 OF THE UNITED STATES CODE
Each of the undersigned, Timothy C. Scott, Ph.D., the President (principal executive officer) of Provectus Biopharmaceuticals, Inc. (the “Company”), and John R. Glass, the Interim Chief Financial Officer (principal financial officer) of the Company, certifies, pursuant to Rule 13a-14(b) under the Securities and Exchange Act of 1934 (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code, that (1) this Quarterly Report on Form 10-Q for the quarter ended September 30, 2017, fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act, and (2) the information contained in this report fairly presents, in all material respects, the financial condition and results of operations of the Company.
This Certification is signed on November 8, 2017.
| By: | /s/ Timothy C. Scott, Ph.D. | |
|
Timothy C. Scott, Ph.D. President (principal executive officer) |
| By: | /s/ John R. Glass | |
|
John R. Glass Interim Chief Financial Officer (principal financial officer) |